Voyager Therapeutics, INC. (VYGR) — SEC Filings

Overview

Voyager Therapeutics, INC. (VYGR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Voyager Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $92.295 million, a substantial rise from $30.515 million in the same period of 2024. Collaboration revenue decreased sharply to $25.038 million for the nine months ended Sept

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 24 neutral, 1 mixed. The dominant filing sentiment for Voyager Therapeutics, INC. is neutral.

Filing Type Overview

Voyager Therapeutics, INC. (VYGR) has filed 5 10-Q, 13 8-K, 2 DEF 14A, 6 SC 13G/A, 1 10-K, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (28)

• Voyager's Losses Mount Amid Plummeting Collaboration Revenue — 10-Q · Nov 10, 2025 Risk: high
  Voyager Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $92.295 million, a substantial ris
• Voyager Therapeutics Files 8-K — 8-K · Sep 2, 2025 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on September 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Voyager's Q2 Loss Widens Amid R&D Surge — 10-Q · Aug 6, 2025 Risk: high
  Voyager Therapeutics, Inc. reported a net loss of $29.5 million for the three months ended June 30, 2025, a significant increase from the net loss of $20.1 mill
• Voyager Therapeutics Announces Corporate Changes and Filings — 8-K · Jun 5, 2025 Risk: medium
  Voyager Therapeutics, Inc. announced on June 3, 2025, a series of significant corporate actions. These include the departure of certain directors and officers,
• Voyager Therapeutics Files 8-K — 8-K · May 6, 2025 Risk: low
  On May 6, 2025, Voyager Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 75 Hayden Avenue,
• Voyager Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 23, 2025 Risk: medium
  Voyager Therapeutics, Inc. filed its DEF 14A on April 23, 2025, for the fiscal year ending December 31, 2025. The filing details executive compensation, includi
• Voyager Therapeutics Files 8-K on Financials — 8-K · Mar 11, 2025 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Pfizer to Acquire Voyager Therapeutics for $3.5 Billion — 8-K · Feb 11, 2025 Risk: medium
  Voyager Therapeutics, Inc. announced on February 11, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $3.5 billion in cas
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Voyager Therapeutics Q3 2024 Update — 10-Q · Nov 12, 2024 Risk: medium
  Voyager Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $178.4 million as of Septe
• Voyager Therapeutics Enters Material Definitive Agreement — 8-K · Sep 5, 2024 Risk: medium
  On September 3, 2024, Voyager Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement
• SC 13G/A Filing — SC 13G/A · Aug 7, 2024
• Voyager Therapeutics Q2 2024 Update — 10-Q · Aug 6, 2024 Risk: medium
  Voyager Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $54.5 million as of June 30, 20
• Voyager Therapeutics Appoints New CMO and CDO, Burns Departs — 8-K · Jun 13, 2024 Risk: medium
  Voyager Therapeutics, Inc. announced on June 11, 2024, the appointment of Dr. Todd M. Batson as Chief Medical Officer and Dr. Sarah L. Sell as Chief Development
• Voyager Therapeutics Sets Annual Meeting for June 27 — 8-K · Jun 6, 2024 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting that its annual meeting of stockholders will be held on June 27, 2024. At this meeting, stock
• Voyager Therapeutics Files 8-K — 8-K · May 16, 2024 Risk: low
  On May 16, 2024, Voyager Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details rega
• Voyager Therapeutics Reports Q1 2024 Results, Focus on Gene Therapy Development — 10-Q · May 13, 2024 Risk: medium
  Voyager Therapeutics, Inc. (VYGR) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Voyager Therapeutics reported Q1 2024 results on May 13, 2024. T
• Voyager Therapeutics Announces 2024 Annual Meeting of Stockholders on June 5 — DEF 14A · Apr 25, 2024 Risk: low
  Voyager Therapeutics, Inc. (VYGR) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Voyager Therapeutics will hold its 2024 Annual Meeting of St
• Voyager Therapeutics Appoints New CMO and CDO — 8-K · Apr 2, 2024 Risk: medium
  Voyager Therapeutics, Inc. announced on March 27, 2024, the appointment of Dr. Sarah Tisch as Chief Medical Officer and Dr. Kevin R. Jones as Chief Development
• Voyager Therapeutics Files 8-K — 8-K · Mar 13, 2024 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on March 13, 2024, reporting events as of February 29, 2024. The filing primarily concerns financial statements and exhi
• Voyager Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
  Voyager Therapeutics, Inc. (VYGR) filed a Annual Report (10-K) with the SEC on February 28, 2024. Voyager Therapeutics, Inc. filed its 10-K report for the fisca
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Discloses Passive Stake in Voyager Therapeutics (VYGR) — SC 13G · Jan 29, 2024
  BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Voyager Therapeutics, Inc.
• Voyager Therapeutics Reports Material Definitive Agreement — 8-K · Jan 8, 2024
  Voyager Therapeutics, Inc. (VYGR) filed an 8-K on January 8, 2024, reporting a material definitive agreement and other events that occurred on January 3, 2024.
• Voyager Therapeutics Files 8-K on Material Agreement & Equity Sales — 8-K · Jan 2, 2024
  Voyager Therapeutics, Inc. filed an 8-K on January 2, 2024, reporting an event on December 28, 2023, related to an entry into a material definitive agreement, r

Related Companies

NBIX · NVS · AZN · SRPT · BIIB · PFE · VGRX

Frequently Asked Questions